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MicroRNA signature refine 
response prediction in CML
Raquel Alves1,2,3, Ana Cristina Gonçalves  1,2,3, Joana Jorge1,2,3, Gilberto Marques4, Dino Luís5, 
André B. Ribeiro  2,5, Paulo Freitas-tavares5, Bárbara oliveiros2,6, António M. Almeida7,8 & 
Ana Bela sarmento-Ribeiro1,2,3,5
microRNAs (miRs) dysregulation have emerged as a crucial step in tumorigenesis, being related with 
cancer development, progression and response to treatment. In chronic myeloid leukaemia (CML), the 
resistance to tyrosine kinase inhibitors (TKI) is responsible for treatment failure and could be linked to 
changes in miRs expression. This work aimed to correlate the expression levels of 3 miRs, miR-21, miR-
26b and miR-451, with response to TKI treatment in CML patients. miR-451 levels at diagnosis were 
significantly higher in patients with optimal response after 6 and 12 months of therapy. Conversely, 
patients without optimal response had highest levels of miR-21. miR-21 and miR-451 appear to be good 
biomarkers of response, able to predict optimal TKI responders (p < 0.05). Using the combined profile 
of both miRs, we create a predictive model of optimal response after one year of treatment. This study 
highlights the role of miR-21 and miR-451 expression levels at diagnosis in predicting which patients 
achieve the optimal response.
MicroRNAs (miRs) are a group of small single-strained non-coding RNAs (≈22 nucleotides of length) that act 
as epigenetic regulators of specific targets by modulating gene expression via translational repression or mRNA 
cleavage1. Although protein inhibition is the expected result of miR function, this is not always an inhibitory 
process. miRs can indirectly activate the expression of some mRNAs by degradation of their natural inhibitors1,2. 
These small RNAs regulate around 80% of the transcriptome and play a key role in multiple cellular processes, like 
proliferation, development, differentiation and apoptosis2.
The dysregulation of miRs expression patterns can have numerous implications including the promotion of 
tumorigenesis3. miRs expression pattern differs according to tissues, cell types and developmental stages, and 
could act as oncomiRs, promoting processes that favour cancer cells, or as tumour suppressor miRs, regulating 
the expression of oncogenes4,5. Aberrant expression of miRs has been reported in solid tumours and haematolog-
ical neoplasia, as chronic myeloid leukaemia (CML)6,7. The presence of BCR-ABL1 is the distinctive molecular 
characteristic of CML and the target for treatment with tyrosine kinase inhibitors (TKI)8. Resistance to imatinib 
and other TKIs has been recognised as the major challenge for CML treatment and monitoring, since some of 
the imatinib-resistant patients had no mutations on BCR-ABL1 oncogene9. Since miRs are potent regulators, they 
may be implicated in the acquisition of drug resistance because they could regulate not only BCR-ABL1 but also 
modulate the expression of genes involved in drug transporter or activation of essential signalling pathways6,10. In 
CML the most deregulated miRs studied include miR-10a, miR-130b, miR-150 and miR-203, but several others 
miRs emerge in the complex network of miR regulation11,12.
Overexpression of the oncomiR miR-21 has been associated with the development of neoplasias where it 
targets many tumour suppressor genes related to proliferation, apoptosis and survival13. One example of miR-21 
targets is PTEN, a negative regulator of the PI3K/AKT pathway, which is often described as deregulated in can-
cer. In addition, levels of miR-21 were correlated with acquisition of resistance to multiple drugs, as gemcitabine 
and TKIs13,14. PTEN is also a target of miR-26b, but the role of this miR in cancer is still controversial, being 
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sometimes described as oncomiR and others as a tumour suppressor miR15,16. Particularly relevant in CML are 
the miRs that target ABL and consequently BCR-ABL1, being some of the most deregulated ones. miR-451, miR-
203 and miR-320a are described as downregulated in CML, since they directly target ABL and BCR-ABL1 acting 
as tumour suppressors, by reducing BCR-ABL oncoprotein expression12,17.
Furthermore, miRs expression is a dynamic process which reflects changes at cellular levels not only at the 
time of neoplasia development but also in progression or response to treatment. These characteristics made the 
expression levels of miR a potential biomarker for diagnosis, prognosis and treatment response18,19.
In this work, we analysed the expression levels of miR-21, miR-26b and miR-451 in CML patients and in vitro 
models, and correlated them with TKI response levels. The potential of each miR as a predictive biomarker was 
explored, with a particular emphasis for the combinatorial miR expression profile.
Results
Differential miRs expression levels at Imatinib-resistant models. To check if the expression levels 
of miR-21, miR-26b and miR-451 may be related with Imatinib resistance, we evaluated the levels of each miR 
in three CML cell lines (one sensitive and two resistant to TKI, the K562-RC and the K562-RD cells respec-
tively). The Imatinib-resistant cells presented different expression levels of miRs compared to the sensitive cell 
line (Fig. 1). The oncomiR miR-21 was up-regulated in both resistant models, with 4.3-fold higher expression 
in K562-RC cells (p = 0.0038; Fig. 1a). Similarly, miR-26b was increased in resistant cells, with 2.0-fold higher 
expression in K562-RD cells (p = 0.0023; Fig. 1b). By opposition, the tumour suppressor miR-451 was down-reg-
ulated in K562-RC and K562-RD cells, with 3.8-fold less expression in the discontinuation model (K562-RD) 
(p = 0.0048; Fig. 1c).
CML patients miRs expression levels at diagnosis. We subsequently assessed the expression of the 
same miRs in CML patients, samples at diagnosis (Fig. 2). Clinical and biological characteristics of our cohort of 
patients were summarised in Table 1. miR-26b and miR-451 were expressed in all patients, the tumour suppres-
sor miR-451 exhibiting the highest expression at diagnosis [7.147 (95% confidence interval (CI): 5.201–8.912; 
Fig. 2c)], and the miR-26b the second one with a median of 0.087 (95% CI: 0.070–0.099; Fig. 2b). miR-21 was 
expressed in 93.3% of patients (28 out of 30 patients) with a median of 0.003 (95% CI: 0.00014–0.00033; Fig. 2a). 
The expression of this miR was inversely correlated with the expression of miR-451 (R = −0.655; p = 0.0002). 
Figure 1. miRs expression profile of imatinib-resistant CML cell lines. Sensitive cell line, K562 cells, was 
used as reference to determine the fold-change of miR-21 (a), miR-26b (b) and miR-451 (c) of resistant cell 
lines, K562-RC and K562-RD cells. miR-21 was higher in K562-RC, while miR-26b was higher in K562-RD. 
Moreover, miR-451 was significantly down-regulated in K562-RD. The results are presented in mean with 95% 
CI of four independent samples and the expression of K562 cell line is represented by dot line. **p < 0.001 
compared with K562 cells.
Figure 2. miRs expression levels in CML patients at diagnosis. The expression levels of miR-21 (a), miR-26b 
(b) and miR-451 (c) were normalised to miR-16 in CML patients at diagnosis time. At diagnosis, miR-451 was 
the miR with the highest expression and miR-21 with the lowest. The results are represented as median with 
interquartile range.
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miR-26b expression was positively correlated with miR-21 expression (R = 0.611; p = 0.001) and inversely asso-
ciated with miR-451 (R = −0.462; p = 0.010).
The observed miR expression levels may be related with the disease phase at diagnosis, since miR-451 shown 
a tendency to be downregulated at accelerated phase or blast crisis [median of 4.28, Interquartile Range (IR) 
1.82–8.92, n = 5)] in comparison with patients in chronic phase (median of 7.31, IR 5.13–10.02, n = 25). However, 
the low number of patients in advanced phases did not allow statistically significant differences to be detected. For 
that it would be necessary at least 68 patients in each group (G power analysis with 80% of power).
TKI Response and miRs expression levels. To confirm if the miRs expression at diagnosis could be 
related with the degree of response achieved after TKI treatment, we evaluated the expression profile according to 
response levels after 6 and 12 months of treatment20. Optimal response was considered when BCR-ABL1 expres-
sion levels were lower than 1% at 6 months and ≤0.1% at 12 months of treatment20. Patients with higher levels of 
miR-451 at diagnosis had a higher rate of optimal response after 6 months (p = 0.039; Fig. 3a). Our results reveal 
that the lower expression of miR-21 (p = 0.019) and higher levels of miR-451 (p = 0.012) were associated with 
patients with optimal response at 12 months of treatment (Fig. 3b). At both time points, the levels of miR-26b 
were higher in patients without optimal response, but the differences were not statistically significant.
To explore the predictive power of miRs expression to predict response to TKI treatment, we performed 
ROC curve analysis (Fig. 4). miR-451 expression discriminated patients with optimal response from those with-
out response after 6 months of treatment (p = 0.038; Fig. 4a). In addition, both miR-451 and miR-21 revealed 
significant potential as response biomarkers at 12 months of TKI (Fig. 4a). The expression of miR-451 was the 
most accurate parameter to predict response with an area under the curve (AUC) of 0.771 (95%CI: 0.594–0.949; 
p = 0.013). At diagnosis, miR-451 expression levels higher than 4.74 and 5.70 were the optimal cut-off values to 
discriminate optimal response after 6 and 12 months of treatment, respectively (Fig. 4b). These cut-off values 
present higher sensitivity, 94.1% at 6 months and 93.3% at 12 months, with a satisfactory specificity of 66.7% and 
64.3% for both time points. Conversely, levels of oncomiR miR-21 below 1.16 × 10−4 at diagnosis was identified 
as the best cut-off value for optimal response at 12 months of treatment. This biomarker revealed the highest 
sensitivity (100%) and also a strong positive predictive value (PPV:100%) and a good negative predictive value 
(NPV: 70%) (Fig. 4b).
miRs profile and response after a year of treatment. Since we identified both miR-21 and miR-451 as 








   Male 16 (53.3) 14 (51.9)
   Female 14 (46.7) 13 (48.1)
Clinical features




   Chronic Phase (%) 25 (83.3)
   Accelerate Phase or Blast Crisis (%) 5 (16.7)
Treatment at analysis time point
TKI (%) 27 (90.0) 22 (81.5)
   Imatinib (%) 26 (96.3) 14 (63.6)
   2nd TKI (%) 1 (3.7) 8 (36.4)
TKI plus INF-α (%) 3 (10.0) 5 (18.5)
   Imatinib (%) 2 (66.7) 4 (80.0)
   2nd TKI (%) 1 (33.3) 1 (20.0)
Response at 6 Months at analysis time point
   Optimal Response (%) 17 (56.7) 24 (88.9)
   Without Optimal Response (%) 9 (30.0) 3 (11.1)
   No determined (%) 4 (13.3)
at 12 Months
   Optimal Response (%) 15 (50.0)
   Without Optimal Response (%) 14 (46.7)
   No determined (%) 1 (3.3)
Table 1. Biodemographic and clinical characteristics of CML patients. TKI: Tyrosine kinase inhibitors; INF-α: 
interferon-alpha.
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Using the optimal cut-off values detected for each miR, we classified patients in four different profiles accord-
ing to miR-21 and miR-451 expression levels: Profile 1: miR-451 > 5.69 and miR-21 < 1.16 × 10−4; Profile 2: 
miR-451 < 5.69 and miR-21 > 1.16 × 10−4; Profile 3: miR-451 > 5.69 and miR-21 > 1.16 × 10−4; Profile 4: miR-
451 < 5.69 and miR-21 < 1.16 × 10−4. After, we correlated these miRs profiles with the probability to achieve 
an optimal response after 12 months of treatment. All patients included in the first profile presented an optimal 
response (8 optimal responses out of 8), while most of those in profile 2 do not reach optimal response (1 optimal 
response out of 10). Risk analysis showed that profile 2 patients have 25 times lower probability to achieve optimal 
response after one year of treatment (OR: 0.040; 95%CI: 0.0039–0.398; p = 0.001). On the other hand, patients 
with profile 1 presented 42 times higher chances to accomplish an optimal response at the same time point (OR: 
42.38; 95%CI: 2.129–843.9; p = 0.0007). Profile 3 was not statistical associated with response (4 optimal responses 
out of 9), and no patient presented profile 4.
In this context, miR-21 and miR-451 levels at diagnosis were used to create a predictive model for an optimal 
response after one year of treatment. From the different regression models tested, the main effect (ME) model that 
takes in consideration both miRs for optimal response, was the most predictive one accounting for a total of 66% 
of the variance (Table 2). Applying this model, we will be able to assess the individual probability of each patient 
to achieve an optimal response (P) Eq. (1).
=






(1)miR miR(19,6 19,6 21 2,2 451)
In Eq. (1), miR21 and miR451 represent the miR expression in a dichotomized form (miR-21 ≤ 1.16 × 10−4 = 0 
and miR-21 > 1.16 × 10−4 = 1; miR-451 > 5.7 = 0 and miR-451 ≤ 5.7 = 1).
Figure 3. Correlation between TKI response and miRs expression levels at diagnosis. Patients were grouped 
according to TKI response in optimal response or without optimal response, reached after 6 and 12 months 
of treatment. The expression levels of miR-21, miR-26b and miR-451 at diagnosis were analysed according to 
the TKI response after 6 (a) and 12 (b) months of treatment. miR-451 was down-regulated in patients without 
optimal response after 6 and 12 months of TKI therapy, while miR-21 was up-regulated in patients without 
optimal response after 12 months of treatment. Statistical differences between groups are reported by the 
p-value.
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miRs expression at follow-up. Due to lack of samples, it was not possible to determine the miRs expres-
sion at diagnosis in the follow-up group. To determine the fold-change of this group, we used the median of each 
miR observed in the diagnosis group as a reference, since the values did not present a normal distribution. mir-21 
was up-regulated 15.0 times during the treatment, while miR-26b and miR-451 were down-regulated 2.4 and 
9.2 times, respectively. Correlating the expression levels with clinical and laboratory data, we observed higher 
levels of miR-21 (p = 0.008; Fig. 5a) and miR-26b (p = 0.008. Figure 5b) in patients that fail 1st line of treatment 
and switch for other TKI. Additionally, miR-26b levels were significantly downregulated in patients with lower 
BCR-ABL1 quantification (p = 0.041; Fig. 5c). Furthermore, we observed that patients with a deeper molecular 
response (MR) presented lower levels of miR-26b than those with MR of 3.0 (MR 4.0 p = 0.032. and MR 4.5 
p = 0.041) (Fig. 5d).
Figure 4. Receiver Operating Characteristic (ROC) curve analysis of miR-451 and miR-21. ROC curves (a) and 
the identification of optimal cut-off values to discriminate optimal response (b) point-out the ability of miR-451 
and miR-21 expression at diagnosis to predict response to TKI treatment at 6 months and 12 months. For each 
curve was represent the Area Under the Curve (AUC) and the respective p-value. RE–Relative Expression; PPV- 
Positive Predictive Value; NPV- Negative Predictive Value.
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Discussion
Most deregulated miRs act on specific signalling pathways that seem to be essential to promote and maintain 
cancer cell survival and growth4. This critical regulatory role, led to associations between miRs expression and 
response to anticancer drugs proposed by several authors10. Our results from in vitro models highlighted the rela-
tion of miR-21 and miR-26b overexpression and miR-451 downregulation with imatinib-resistant phenotype. As 
expected, an unbalance between oncomiRs and tumour suppressor miRs were observed in the resistant models. 
In line with in vitro models results, we found a correlation between miR-21 and miR-451 expression at diagnosis 
with the response to TKI treatment. In our cohort, we observed that the optimal response to TKI after 6 months 
was related to high levels of miR-451. After 12 months of treatment, patients with an optimal response presented 
not only high levels of miR-451 but also low levels of miR-21, compared to those without optimal response.
miR-451 acts as a tumour suppressor and has been reported to be downregulated in some neoplasias, such as 
gastric cancer, glioblastoma and leukaemia21–23. Particularly in CML, the expression of miR-451 was associated 
with a favourable prognosis, since this miR targets ABL and BCR-ABL1 directly12. According to Lopotová et al.24, 
the miR-451 expression is downregulated in CML at diagnosis compared with healthy controls, and this could 
be due to BCR-ABL activity25. The same authors suggested a reciprocal regulatory loop between this miR and 
BCR-ABL1 levels that could be interrupted by imatinib treatment24. This interaction could have a critical impact 








Raw Aggrement (%) 79.31 79.31 79.31 79.31
kappa (Cohen) 0.59 0.58 0.58 0.58
Sensitivity (%) 100.00 64.29 64.29 64.29
Specificity (%) 60.00 93.33 93.33 93.33
PPV (%) 70.00 90.00 90.00 90.00
NPV (%) 100.00 73.68 73.68 73.68
acuracy (Youden) 60.00 57.62 57.62 57.62
R2 (Nagelkerke) 0.56 0.45 0.45 0.66
AIC 28.44 32.40 32.40 26.36
Table 2. Statistical measures for predicting models for optimal response. PPV: Positive predictive value; NPV: 
Negative predictive value; AIC: Akaike information criterion.
Figure 5. Analysis of miR-21 and miR-26b fold-change in patients under TKI treatment. miR-21 (a) and miR-
26b (b) fold-change were analysed according to the number of TKI that patients were exposed. The miR-26 
expression levels were also studied in patients stratified according to BCR-ABL1 values (c) and to molecular 
response rates (d) Higher levels of miR-21 and miR-26b were detected in patients that fail 1st line of treatment, 
whereas miR-26b were down-regulated in patients with lower BCR-ABL1 levels and also in patients with deeper 
responses to treatment (MR 4.0 and MR 4.5). Statistical differences between groups are reported by the p-value.
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miR-451 levels were able to predict patients that will achieve response at an early point (6 months) and after one 
year of treatment, with very good sensitivity and specificity. In the same line, Su et al. (2015) suggested miR-451 
as a potential prognostic biomarker in gastric cancer23. The introduction of new biomarkers, as could be the case 
of miR-451, will improve patient monitoring and could have an impact on therapeutic selection.
With opposite functions, miR-21 is one of the most overexpressed miRs in solid and haematological tumours13. 
We observed that low levels of this miR at CML diagnosis were related with the achievement of optimal response 
to TKI therapy. miR-21 present multiple targets as PTEN, PDCD4 and TIMPs that contribute to the promotion of 
proliferation, survival and invasion pathways, however according to cell type, the principal mechanism of action 
may be different13,26. In some cells, it could be related to the up-regulation of BCL-2 to prevent apoptosis, while 
in others the most significant effect may be the inhibition of PTEN and consequently the activation of PI3K/
AKT pathway13,27. In CML, BCR-ABL, with its constitutive tyrosine kinase activity, stimulates multiple signalling 
pathways such as PI3K/AKT and MAPK/ERK. The downregulation of PTEN and inhibition of PDCD4 has been 
described as the most crucial action of miR-21 in CML cells26,28. The correlation between miR-21 expression and 
resistance to anticancer agents, describe by us and other groups, highlight the possible clinical application of this 
miR as a target for therapy29. Several groups showed an increase in cell death and a synergistic effect with other 
drugs when miR-21 was inhibited by antagomiRs or some molecules that modulate miR-21, as curcumin30–32. In 
this work, we did not test miR-21 as a therapeutic target, but we assess the power as a tool for predicting a good 
response to TKI treatment. Levels of miR-21 measured at diagnosis work as a biomarker of response after one 
year of TKI therapy. In childhood B cell acute lymphoblastic leukaemia, the same miR is an independent prognos-
tic marker, were high levels were associated with poor response and shorter overall survival33.
Using a single measure to predict prognosis, progression, response and many other aspects seem very simple 
and sometimes difficult to explain the cell complexity. Based on this, we look for the combinatorial miR expres-
sion profile since two miRs showed biomarkers characteristics. Based on cut-off values identified for miR-21 and 
miR-451, we created 4 different profiles to assess the risk/ probability to achieve optimal response after 12 months 
of TKI treatment. Patients with a high level of miR-451 and low levels of the oncomiR miR-21 at diagnosis (pro-
file1) presented 42 times more probability of achieving an optimal response. According to miRs functions, profile 
1 appears as the best combination possible supporting a more controlled environment against cancer cells growth. 
In opposition, profile 2, which comprehend higher oncomiRs expression, lead to a very low probability of these 
patients reaching optimal response.
By identifying patients at high risk of relapse or progression under treatment, we can prevent several compli-
cations and disease progression. Improving the disease monitoring or introducing changes in therapeutic options 
for these subgroups of patients could be the best approach to achieve better results. These predictive models 
might play an important role in identifying subgroups of patients based on clinical and biological features. Sokal, 
EURO, EUTOS and ELTS are scores used in CML for discriminating overall survival (Sokal and EURO), pre-
dicting complete cytogenetic remission (CCgR) 18 months after the start of therapy, and predict the probability 
of CML related death, respectively34–37. These scores are based on age, spleen size and haematological parameters 
at diagnosis, such as basophils, blast cells and platelets. However, none of them were designed to predict optimal 
response to TKI treatment. Using our miRs results, we create a predictive model (Eq. 1) to assess the probability 
of each patient achieving and optimal response to TKI treatment after one year of therapy. The identification of 
new biomarkers of response/resistance to TKI is in constant progress, and several molecules present good dis-
criminating power, namely specific gene signatures. Nevertheless, independent validation of all new biomarkers 
and scores would be very helpful to implement in the clinic the most accurate one to predict the optimal response.
In order to increase the number of patients studied and due to the impossibility of obtaining samples at diag-
nosis from all patients, we use the medians of miRs expression at diagnosis to estimate the fold-change in miR 
expression induced by TKI treatment. Although not statistically significant, the expression levels of miR-26b at 
diagnosis was higher in patients that did not reach optimal response with TKI. However, this miR presented some 
relevance at follow-up measures in a group of treated patients. The majority of studies describe miR-26b as a 
tumour suppressor miR that can inhibit cell proliferation in breast cancer, hepatocellular carcinoma and cervical 
cancers16,38,39. However, some contradictory results have suggested that this miR could act as oncomiR. Palumbo 
et al.15 revealed that the regulation of PTEN in pituitary tumour cells is mediated by miR-26b action15. miR-26b 
by targeting PTEN, as also describe to miR-21, leave the PI3K/AKT signalling pathway without regulation, pro-
moting tumorigenesis. In agreement with these authors, our results suggest that lower levels of miR-26b were 
associated with a good response to the first line of treatment and with more profound responses. These results 
suggest that miR-26b might be an indicator of good responses levels.
The link between miR-21, miR-26b and miR-451 and TKI response levels need to be validated in a bigger 
cohort of patients before moving into clinical practice. On the other hand, understanding the crucial role of these 
miRs in disease progression and treatment response might be very useful for exploring these miRs as a new ther-
apeutic target in CML. In conclusion, expression levels of miR-21 and miR-451 at diagnosis play a crucial role in 
CML response to TKI treatment and may constitute a new potential biomarkers of response and for the guidance 
of therapeutic options.
Material and Methods
Cell lines. K562 cells sensitive to Imatinib and two Imatinib-resistant models (K562-RC and K562-RD cells) 
were used as in vitro models of CML. The sensitive cell line was obtained from ATCC, and the Imatinib-resistant 
cell lines were developed in our laboratory based on two strategies: a continuous exposure (K562-RC) and a dis-
continuous exposure to Imatinib (K562-RD), as described in Alves et al.40.
study population. Fifty-seven CML patients were enrolled in the present study and recruited at Clinical 
Hematology Department of Centro Hospitalar Universitário de Coimbra (CHUC), Portugal. Patients were 
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grouped according to different time points: at diagnosis (diagnosis group, n = 30) and follow-up (follow-up 
group, n = 27). Clinical and biological characteristics were summarised in Table 1. Treatment response criteria 
were defined according to the European Leukemia Net (ELN) guidelines20, where optimal response corresponds 
to BCR-ABL levels lower than 1% at 6 months and ≤0.1% at 12 months. Patients that presented levels higher 
than the established cut-off were incorporated in “without optimal response” group. The study was conducted 
according to the Helsinki Declaration, and all participants provided informed consent for participation before 
enrolment. The Ethics Committee of the Faculty of Medicine (University of Coimbra, Portugal) approved all 
research procedures (ref. CE-014/2014).
RNA extraction, cDNA synthesis, and real-time PCR. Total RNA was extracted from CML patients’ 
samples and cell lines using the mirVana miRNA Isolation Kit (Ambion), according to the manufacturer’s pro-
tocol. RNA quantity and quality were measured using a NanoDrop ND-1000 spectrophotometer. TaqMan® 
Advanced miRNA cDNA Synthesis Kit (Applied Biosystems) was used to convert 10 ng of total RNA, according 
to the manufacturer’s protocol. Briefly, this kit included several steps: the Poly(A)-tailing reaction, the ligation 
reaction, reverse transcriptase reaction followed by a miR-Amp reaction. cDNA was diluted to 1:10 with DNase/
RNase free water before use. The levels of miR-21, miR-451, miR-26b and miR-16 were determined in each 
sample. The quantitative real-time polymerase chain reaction (qPCR) was performed using TaqMan Advanced 
miRNA Assays (Applied Biosystems) in a QuantStudio 3 system (Applied Biosystems). For each miR, we used 
one TaqMan Advanced miRNA Assays with specific probes and primers. miR-16 exhibited the most constant 
expression levels between the samples and was identified as endogenous control by relative quantification soft-
ware (Thermo Fisher Scientifc). Based on this and supported with statistical analysis (Supplementary Figure S1) 
and miR-16 was used as endogenous control. Relative expression levels of the studied miRNAs were calculated 
using the relative quantification 2−ΔCT method and normalised with miR-16 (ΔCT = CT of target–CT of miR-
16). The fold change was calculated by 2−ΔΔCT method using K562 as a reference for cell lines and the expression 
at diagnosis for patients follow-up.
statistical analysis. The statistical analyses were performed using IBM.SPSS®, version 22, except when oth-
erwise indicated. Normal distribution was tested and the following analyses were performed according to these 
results. Differences between two groups were assessed by nonparametric Mann-Whitney U test and for three or 
more groups by nonparametric Kruskal-Wallis test followed by Dunn’s multiple comparison tests. The receiver 
operating characteristic (ROC) curves analysis was performed to evaluate the variables accuracy as biomarkers. 
For each ROC curve, an optimal cut-off point was determined by the maximum Youden’s J Index, which corre-
sponds to the value of the parameter that maximised the sum of specificity and sensitivity. The positive predictive 
value (PPV) and negative predictive value (NPV) were calculated for each identified biomarker. The association 
between profiles and the optimal response was analysed by calculating the odds ratio (OR) and its 95% confidence 
interval (CI), using Fisher’s exact test with GraphPad Prism version 6.0. G power analysis was performed Gpower 
software (version 3.1.9.2). The formulas for predicting an optimal response using both miR-21 and miR-451 
expression levels were achieved using R software and its general linear model (glm) function with binomial family 
and logit link, either using continuous or binary miR profile, considering the single effect, main effect, interaction 
or full factorial models. The Akaike information criterion (AIC’s) minimal value identified the best model. All the 
statistical tests were considered significant when p < 0.05.
Data Availability
All data generated or analysed during this study are included in this published article.
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